Merck and Bristol Myers Offer Different Dividend Profiles
Merck and Bristol Myers Squibb both lifted their 2026 sales forecasts, but their dividends differ in yield and coverage. Bristol Myers yields 4.3% and paid out 45% of free cash flow over the year to June 30, 2026, while Merck yields 2.4% and paid out 52%. Merck has raised its dividend faster recently and has stronger interest coverage, while Bristol Myers faces key trial results for milvexian and Cobenfy in 2027.
Both pharmaceutical companies raised their 2026 sales forecasts after second-quarter results. Bristol Myers Squibb's dividend yield is 4.3%, while Merck's is 2.4%. For the twelve months ending June 30, 2026, Bristol Myers distributed 45% of free cash flow as dividends; Merck distributed 52%.
Merck increased its dividend by 5.1% in fiscal 2025, compared with 2.9% at Bristol Myers. Merck also showed stronger interest coverage: 13.47x versus 9.07x. Bristol Myers's upcoming milestones include trial results for milvexian and Cobenfy, expected in 2027.
Income-focused investors, including retirees and pension funds, may weigh Bristol Myers's higher yield against Merck's faster dividend growth and stronger interest coverage. If Bristol Myers's 2027 trial results disappoint, its payout capacity could face pressure; Merck's Keytruda concentration may pose similar risks. Patients and employees could be indirectly affected if dividend priorities shape research spending or business decisions, though the immediate effect is likely limited to shareholders and corporate strategy.